In this collaboration, tumor specimens from subjects treated with IRX-2 and control subjects will be analyzed by the collaborating company using gene analysis technology in order to characterize the action of IRX-2 immunotherapy at the molecular level.
IRX’s lead product candidate, IRX-2, is designed to restore the immune system.
The IRX-2 immunomodulator includes multiple cytokine components that work to activate different arms of the immune system.
IRX president and CEO John Hadden II said they are hopeful that these studies will further evidence the potential of IRX-2 to effect an immune based attack on a cancer patient’s tumor.